NASDAQ: ETON - Eton Pharmaceuticals, Inc.

Yield per half year: +71.15%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Eton Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning.

more details
It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-11-13
ISIN US29772L1089
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.etonpharma.com
Цена ао 13.38
Change price per day: +2.92% (13.72)
Change price per week: +23.1% (11.47)
Change price per month: -9.37% (15.58)
Change price per 3 month: +5.22% (13.42)
Change price per half year: +71.15% (8.25)
Change price per year: +338.51% (3.22)
Change price per 3 year: +270.6% (3.81)
Change price per 5 year: +392.47% (2.8672)
Change price per year to date: +14.98% (12.28)
All parameters

Underestimation

Title Value Grade
P/S 8.65 1
P/BV 13.81 1
P/E 0 0
EV/EBITDA -124.21 0
Total: 1.63

Efficiency

Title Value Grade
ROA, % -7.09 0
ROE, % -19.16 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0412 10
Total: 7.2

Growth impulse

Title Value Grade
Yield Revenue, % 99928.21 10
Yield Ebitda, % -90.2 0
Yield EPS, % -89.22 0
Total: 2
More

Institutions Volume Share, %
Opaleye Management Inc. 2529887 9.85
Vanguard Group Inc 1027688 4
Westside Investment Management, Inc. 563110 2.19
Acuitas Investments LLC 492054 1.92
Paradigm Capital Management 300000 1.17
Blackrock Inc. 284241 1.11
Bridgeway Capital Management, Inc. 253362 0.99
Geode Capital Management, LLC 227256 0.88
Parkman Healthcare Partners LLC 199168 0.78
Ameriprise Financial, Inc. 161928 0.63



Head Job title Payment Year of birth
Mr. Sean E. Brynjelsen President, CEO & Director 939.42k 1972 (53 years)
Mr. James R. Gruber CPA CFO, Treasurer & Secretary 554.44k 1972 (53 years)
Mr. David C. Krempa Chief Business Officer 547.86k 1989 (36 years)
Mr. Kevin Guthrie Executive VP of Commercial Operations N/A
Danka Radosavljevic Senior Vice President of Quality & Operations
Mr. Scott Grossenbach Vice President of Sales Operations

Address: United States, Deer Park. IL -, 21925 W. Field Parkway - open in Google maps, open in Yandex maps
Website: https://www.etonpharma.com